OF
TRVI icon

Optimize Financial’s Trevi Therapeutics TRVI Stock Holding History

Optimize Financial’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$593K Sell
31,780
-110
-0.3% -$1.6K 0.21% 97
2026
Q1 		$380K Sell
31,890
-29,593
-48% -$331K 0.19% 204
2025
Q4 		$770K Buy
61,483
+884
+1% +$10.2K 0.39% 58
2025
Q3 		$554K Buy
+60,599
New +$454K 0.29% 96

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Optimize Financial's TRVI Position: Q2 2026 in Review

Optimize Financial reduced its Trevi Therapeutics (TRVI) stake by 0.34% in Q2 2026, selling an estimated $1.6K and leaving 31,780 shares worth $593K. The position accounts for 0.21% of the portfolio, ranked #97.

Optimize Financial first reported a position in TRVI in Q3 2025 and has held it in 4 quarters since. The position peaked at $770K in Q4 2025. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Optimize Financial held 31,780 shares of Trevi Therapeutics worth $593K as of Q2 2026.
  • Optimize Financial sold 110 Trevi Therapeutics shares in Q2 2026, an estimated $1.6K.
  • Trevi Therapeutics made up 0.21% of Optimize Financial's portfolio in Q2 2026, its #97 holding.
  • Optimize Financial first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optimize Financial's Trevi Therapeutics position peaked at $770K in Q4 2025.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Optimize Financial's 13F filing for Q2 2026, filed 27 Aug 2026.